102 related articles for article (PubMed ID: 1078395)
1. 780 SE: a new type of hypolipemic agent. Comparative assays in rats.
Duhault J; Boulanger M; Beregi L; Sicot N; Bouvier F
Atherosclerosis; 1976; 23(1):63-72. PubMed ID: 1078395
[TBL] [Abstract][Full Text] [Related]
2. [Comparative effects of clofibrate and tiadenol on the metabolism of cholesterol in rats and hamsters. I. Comparative action of clofibrate and tiadenol on hepatic and intestinal biosynthesis of cholesterol in hamsters and rats].
Rousselet F; Fredj G; Clenet M
Ann Pharm Fr; 1986; 44(4):269-76. PubMed ID: 3566092
[No Abstract] [Full Text] [Related]
3. Action of tiadenol and clofibrate on biliary excretions of cholesterol and bile salts in rats.
Fredj G; Clenet M; Cuchet P; Rousselet F; Rozé C
Digestion; 1979; 19(4):228-36. PubMed ID: 478204
[TBL] [Abstract][Full Text] [Related]
4. Effects of clofibrate and tiadenol on the elimination of lipids and bile acids in rat bile.
Cuchet P; Morrier C; Cand F; Keriel C
Lipids; 1981 Oct; 16(10):732-8. PubMed ID: 7300592
[TBL] [Abstract][Full Text] [Related]
5. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
Sirtori M; Montanari G; Gianfranceschi G; Malacrida MG; Battistin P; Morazzoni G; Tremoli E; Colli S; Maderna P; Sirtori CR
Atherosclerosis; 1983 Nov; 49(2):149-61. PubMed ID: 6365105
[TBL] [Abstract][Full Text] [Related]
6. [Comparative effects of clofibrate and tiadenol on the metabolism of cholesterol in rats. II. Comparative action of clofibrate and tiadenol on biliary and fecal excretion of cholesterol and its metabolites in rats].
Fredj G; Clenet M; Rousselet F
Ann Pharm Fr; 1986; 44(5):347-54. PubMed ID: 3579157
[No Abstract] [Full Text] [Related]
7. Experimental hyper-beta-lipoproteinemia and its amelioration by a novel hypolipidemic agent.
Kobayakawa T; Osuga K; Yasuda H
Atherosclerosis; 1978 Jul; 30(3):219-25. PubMed ID: 209804
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs.
Franceschini G; Poli A; Catapano AL; Gatti E; Sirtori M; Gianfranceschi G; Sirtori CR
Atherosclerosis; 1981; 40(3-4):245-55. PubMed ID: 7332603
[TBL] [Abstract][Full Text] [Related]
9. Changes in lipid metabolizing enzymes of hepatic subcellular fractions from rats treated with tiadenol and clofibrate.
Berge RK; Bakke OM
Biochem Pharmacol; 1981 Aug; 30(16):2251-6. PubMed ID: 7295339
[No Abstract] [Full Text] [Related]
10. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat.
Rozé C; Cuchet P; Souchard M; Vaille C; Debray C
Eur J Pharmacol; 1977 May; 43(1):57-64. PubMed ID: 862664
[TBL] [Abstract][Full Text] [Related]
11. Experimental studies on pharmacology, metabolism and toxicology with tiadenol-disulfoxide. Dissociation of lipid lowering effects and the induction of peroxisomal and microsomal drug-metabolizing enzymes.
Maffei Facino R; Carini M; Tofanetti O; Casciarri I; Longoni E
Arzneimittelforschung; 1987 Jun; 37(6):682-91. PubMed ID: 3663266
[TBL] [Abstract][Full Text] [Related]
12. [Comparative biochemical and ultrastructural study of the hepatic response induced in the rat by 2 hypolipemic agents: clofibrate and itanoxone].
Gendre PM; Marcelon G; Delhon A; Lauressergues H; Fauran F
J Pharmacol; 1984; 15(2):209-22. PubMed ID: 6738078
[TBL] [Abstract][Full Text] [Related]
13. [Effects on the serum lipids of bis (hydroxy-2 ethylthio) 1,10 decane (LL 1558) and clofibrate, based on 91 cases of primary hyperlipoproteinemia].
Rouffy J
Sem Hop Ther; 1973 Jan; 49(1):31-6. PubMed ID: 4712022
[No Abstract] [Full Text] [Related]
14. Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats.
Serradas P; Blondel O; Bailbe D; Portha B
Diabetes; 1993 Apr; 42(4):564-70. PubMed ID: 8454107
[TBL] [Abstract][Full Text] [Related]
15. Nutritional & pharmacologic management of hyperlipoproteinemia.
Pickering JE
Angiology; 1982 Sep; 33(9):577-80. PubMed ID: 6957154
[TBL] [Abstract][Full Text] [Related]
16. Effect of hypolipidemic compounds on lauric acid hydroxylation and phase II enzymes.
Thomas H; Schladt L; Knehr M; Post K; Oesch F; Boiteux-Antoine AF; Fournel-Gigleux S; Magdalou J; Siest G
Biochem Pharmacol; 1989 Jun; 38(12):1963-9. PubMed ID: 2500933
[TBL] [Abstract][Full Text] [Related]
17. Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats.
Russell JC; Graham SE; Dolphin PJ; Amy RM; Wood GO; Brindley DN
Atherosclerosis; 1997 Jul; 132(2):187-97. PubMed ID: 9242964
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological effects of 780SE (992) on hyperlipidaemic and obese rats.
Duhault J; Boulander M; Beregi L
Postgrad Med J; 1975; 51 Suppl 1():99-104. PubMed ID: 1219688
[No Abstract] [Full Text] [Related]
19. [Effects of chronic administration of benfluorex on the pharmacokinetics of iodine 123 labelled insulin in Zucker obese rats (fa/fa)].
Sodoyez JC; Sodoyez-Goffaux F
Presse Med; 1992 Sep; 21(28):1336-9. PubMed ID: 1438103
[TBL] [Abstract][Full Text] [Related]
20. [New derivatives of clofibrate and probucol. Preliminary study of their hypolipemic activity].
de Meglio P; Ravenna F; Manzardo S; Gentili P; Riva M
Farmaco Sci; 1985 Nov; 40(11):833-44. PubMed ID: 4085644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
